Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes~* Patients treated by metformin and/or sulfonylureas (or glinides) and/or acarbose and/or insulin,~* HbA1C \>= 7 %,~* Patients who gave their written consent.~For the kinetic substudy:~* Patients who have the typical features of diabetic dyslipidemia (triglycerides \>= 1.50 g/l and/or HDL\<0.50 g/l \[women\], 0.40 g/l \[men\])~Exclusion Criteria:~* Treatment with thiazolidinediones or other Glucagon-like peptide-1(GLP1) agonist.~* No treatment with a Dipeptidyl peptidase-4 (DPP4) inhibitor during the 3 previous months,~* Renal or hepatic failure,~* Contra-indication for proton-spectroscopy (pacemaker, implantable prosthesis,..),~* Pregnancy.~For the kinetic substudy:~* Patients on hypolipidemic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).